Leiutis Pharma’s synthetic CBD therapy for anxiety disorders gets CDSCO nod New Delhi: Leiutis Pharmaceuticals LLP has announced that the Central Drugs Standard control organization (CDSCO) has granted regulatory approval to its collaboration partner Zenara Pharma to manufacture and market its proprietary Synthetic Cannabidiol Oral Solution 150- mg/mL for the management of mild to moderate anxiety disorders when used in conjunction with cognitive behaviour therapy (CBT) the product is to be prescribed only by psychiatrists. At Amaravathi Rare Diseases Organization (ARDO), we believe that every medical innovation brings new hope to patients and their families. Advancements in research and therapeutic development are essential for improving quality of life and expanding treatment options.